Cocaine Increases Human Immunodeficiency Virus Type 1 Neuroinvasion Through Remodeling Brain Microvascular Endothelial Cells
Overview
Neurology
Authors
Affiliations
Cocaine is a suspected cofactor in human immunodeficiency virus (HIV)-associated dementia but cocaine's effects are not clear. Herein the authors describe investigations of the mechanisms by which cocaine increases HIV-1 invasion through brain microvascular endothelial cells (BMVECs). Cocaine binds to a site on BMVECs, which is not a biogenic amine transporter, a binding site for estrogen, or a muscarinic receptor and for which benztropine and tamoxifen have the highest affinity. Cocaine treatment of BMVECs disrupts intercellular junctions and induces cell ruffling, which could account for their increased permeability and decreased electrical resistance. HIV-1 enters BMVECs by macropinocytosis and is transported to lysosomes and inactivated. In cocaine-treated BMVECs, the virus enters and persists in large cytoplasmic "lakes." Cocaine exposure of BMVECs up-regulates transcription of genes important in cytoskeleton organization, signal transduction, cell swelling, vesicular trafficking, and cell adhesion. The toxicity of cocaine for the blood-brain barrier may lead to increased virus neuroinvasion and neurovascular complications of cocaine abuse.
MicroRNAs in HIV infection: dual regulators of viral replication and host immunity.
Mansour R, El-Sayyad G, Rizk N, Mageed S, Basiouny M, El-Sayed S Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 40029387 DOI: 10.1007/s00210-025-03893-7.
Annadurai N, Kanmogne G Cells. 2024; 13(17.
PMID: 39272987 PMC: 11393916. DOI: 10.3390/cells13171415.
Neurovascular effects of cocaine: relevance to addiction.
Clare K, Park K, Pan Y, Lejuez C, Volkow N, Du C Front Pharmacol. 2024; 15:1357422.
PMID: 38455961 PMC: 10917943. DOI: 10.3389/fphar.2024.1357422.
Substance abuse and neurodegenerative diseases: focus on ferroptosis.
Guo C, Chen L, Wang Y Arch Toxicol. 2023; 97(6):1519-1528.
PMID: 37100932 DOI: 10.1007/s00204-023-03505-4.
Yang J, Betterton R, Williams E, Stanton J, Reddell E, Ogbonnaya C Pharmaceutics. 2022; 14(5).
PMID: 35631535 PMC: 9144323. DOI: 10.3390/pharmaceutics14050949.